Spago on the increased dose in Tumorad-01
Автор: BioStock
Загружено: 2025-04-03
Просмотров: 2972
Описание:
In March, Spago Nanomedical announced that the independent Data Monitoring Committee had recommended a dose escalation in the ongoing phase I/IIa study with the company’s cancer drug candidate. This marks an important step in the study, which Paul Hargreaves, CDO at Spago Nanomedical, discusses further in an interview with BioStock.
0:00 Intro
0:30 Tumorad-01
1:07 Data behind dose increase
1:47 Why is the increase significant?
2:12 Timeline
2:46 How does the study help treatment planning?
3:34 Key objectives of next study phase
4:09 Feedback from clinical sites
Subscribe and follow BioStock on:
YouTube https://bit.ly/Biostock
LinkedIn: / biostock
Facebook: / biostock.se
https://www.biostock.se/
#BioStock #LifeScience #SpagoNanomedical
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
